UroGen Pharma Announces Public Offering of Stock and Warrants


PRINCETON – UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on developing treatments for urothelial cancer and specialty cancers, today announced the launch of an underwritten public offering. The offering includes the sale of common stock and pre-financing warrants, with final terms subject to market conditions.

The company also intends to provide underwriters with a 30-day option to purchase an additional 15% of the number of shares in the offering. UroGen has not disclosed the size or specific terms of the offering. TD Cowen and Guggenheim Securities are acting as joint bookrunners, Oppenheimer & Co. is acting as lead manager and Ladenburg Thalmann is acting as co-manager.

The offering is being made pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (SEC) on November 29, 2022. Obtain.

UroGen Pharma, headquartered in Princeton, New Jersey, with operations in Israel, is known for its proprietary RTGel® reverse thermal gel technology. The platform is designed to enhance the effectiveness of existing drugs by allowing prolonged exposure of urinary tract tissue to drugs. UroGen's product pipeline includes treatments for upper urinary tract urothelial cancer and non-surgical ablative treatments for low-grade, non-muscle-invasive bladder cancer.

This announcement contains forward-looking statements regarding the completion of the Offering and the potential benefits of the Company's technology. However, these are subject to market risks and uncertainties that may materially affect actual results.

This news article is based on UroGen Pharma Ltd.'s press release statement and does not constitute an offer to sell or a solicitation of an offer to buy any securities. The completion and terms of the public offering are not guaranteed and depend on market conditions and other factors.

Investment Professional Insights

As UroGen Pharma Ltd. (NASDAQ: URGN ) begins its public offering, investors are paying close attention to the company's financials and market performance. InvestingPro data shows that UroGen has a market value of US$662.63 million, showing its important position in the biotech industry. As of the first quarter of 2024, the company's gross profit margin for the past 12 months was as high as 89.53%, highlighting its ability to effectively manage costs and maintain strong revenue margins, with revenue growing 24.0% during the same period.

Despite the lack of dividend and profitability concerns, UroGen has shown solid market returns, returning 60.0% over the last year and a whopping 50.35% over the past week. These numbers indicate strong investor confidence and that the market is likely to react favorably to the company's strategic moves, including its recent issuance announcement.

InvestingPro Tips suggests that UroGen's balance sheet reflects a positive financial position, with more cash than debt, which is a reassuring sign for investors considering the risks inherent in the biotech industry. Additionally, the company's liquid assets exceed its short-term debt, further demonstrating financial stability. However, analysts are cautious, as evidenced by lowered earnings estimates for the period ahead and a lack of expected profitability for this year.

For investors looking for more in-depth analysis, InvestingPro also offers other InvestingPro Tips. Take advantage of these insights and use coupon codes PRONEWS24 Enjoy an additional 10% discount on yearly or annual Pro and Pro+ subscriptions. With 12 additional tips listed on InvestingPro, investors can fully understand UroGen Pharma's potential and make more informed decisions.

This article was generated with the support of artificial intelligence and reviewed by an editor. For more information, please see our terms and conditions.





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *